LXRX to expect Phase III HCM data in Q1; resubmits type 1 diabetes NDA
LXRX is advancing sotagliflozin in HCM with Phase III data expected in Q1. The company is also preparing a type 1 diabetes NDA resubmission after meeting FDA safety requirements.
This is a real-time flash headline. A verified provider body is not available, so SquawkNews does not present it as a full article.